# BE Study of Two Formulations of Rivaroxaban 2.5 mg in Healthy Subjects

> **NCT05418803** · PHASE1 · COMPLETED · sponsor: **Yuhan Corporation** · enrollment: 34 (actual)

## Conditions studied

- Healthy Volunteer

## Interventions

- **DRUG:** YHP1807 Tab. 2.5mg
- **DRUG:** YHR1901 Tab. 2.5mg

## Key facts

- **NCT ID:** NCT05418803
- **Lead sponsor:** Yuhan Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-01-28
- **Primary completion:** 2020-02-14
- **Final completion:** 2020-02-14
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2022-06-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05418803

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05418803, "BE Study of Two Formulations of Rivaroxaban 2.5 mg in Healthy Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05418803. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*